CLDI (Calidi Biotherapeutics) Total Equity: $4.94 Mil (As of Mar. 2026)


CLDI Calidi Biotherapeutics Inc CLDI
12 GF Score
Price $0.16
! 1 Warning Sign
View Full Analysis

What is Calidi Biotherapeutics Total Equity?

Calidi Biotherapeutics CLDI +0.64% 12 Total Equity is $4.94 Mil as of Mar. 2026. GuruFocus rates CLDI with a GF Score™ of 12/100. The stock has 1 warning sign investors should review.

Calidi Biotherapeutics's total equity for the quarter that ended in Mar. 2026 was $4.94 Mil.

This is Residual interest, including minority interest, that remains in the assets of the enterprise after deducting its liabilities. Equity is increased by owners’ investments and by comprehensive income, and it is reduced by distributions to the owners.

Calidi Biotherapeutics Total Equity Historical Data

* Premium members only.

The historical data trend for Calidi Biotherapeutics's Total Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Calidi Biotherapeutics Total Equity Chart

Calidi Biotherapeutics Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Equity
Get a 7-Day Free Trial -31.61 -50.44 -8.24 1.97 3.76

Calidi Biotherapeutics Quarterly Data
Dec20 Dec21 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 7.30 2.08 7.20 3.76 4.94
CLDI
12GF Score
Calidi Biotherapeutics Inc CLDI
Total Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Calidi Biotherapeutics Total Equity Calculation

Total Equity and Total Liabilities are the two components for Total Assets.

Calidi Biotherapeutics's Total Equity for the fiscal year that ended in Dec. 2025 is calculated as

Total Equity=Total Assets(Q: Dec. 2025 )-Total Liabilities(Q: Dec. 2025 )
=8.857-5.098
=3.76

Calidi Biotherapeutics's Total Equity for the quarter that ended in Mar. 2026 is calculated as

Total Equity=Total Assets(Q: Mar. 2026 )-Total Liabilities(Q: Mar. 2026 )
=9.591-4.656
=4.94

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Equity →
What does a Total Equity of $4.94 Mil mean?
Calidi Biotherapeutics (CLDI) has a Total Equity of $4.94 Mil as of Mar. 2026. The total amount of equity as record on a company's balance sheet. View historical data for Calidi Biotherapeutics and its competitors.
Is Calidi Biotherapeutics' Total Equity too high?
Calidi Biotherapeutics' current Total Equity is $4.94 Mil. Overall, Calidi Biotherapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Calidi Biotherapeutics' Total Equity compare to CMND and BIXT?
Calidi Biotherapeutics' Total Equity of $4.94 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Equity for a Biotechnology company?
A good Total Equity depends on the Biotechnology industry context. However, Total Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Equity mean?
A high Total Equity can signal that a stock is expensive relative to its fundamentals. The total amount of equity as record on a company's balance sheet. View historical data for Calidi Biotherapeutics and its competitors. Calidi Biotherapeutics's current Total Equity is $4.94 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Calidi Biotherapeutics stock overvalued right now?
Calidi Biotherapeutics (CLDI) has a current Total Equity of $4.94 Mil. The current Total Equity is $4.94 Mil. Calidi Biotherapeutics' overall GF Score™ is 12/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Equity calculated?
Total Equity is calculated from a company's financial statements. For Calidi Biotherapeutics (CLDI), the current Total Equity is $4.94 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Calidi Biotherapeutics Business Description

Address 4475 Executive Drive, Suite 200, San Diego, CA, USA, 92121
Calidi Biotherapeutics Inc is a biotechnology company pioneering the development of targeted therapies with the potential to deliver genetic medicines to distal sites of disease. The company's proprietary RedTail platform features an engineered enveloped oncolytic virus designed for systemic delivery and targeting of metastatic sites. Its technology is intended to shield the virus from immune clearance, allowing virotherapy to effectively reach tumor sites, induce tumor lysis, and deliver potent genetic medicine(s) to metastatic locations. Its product candidates include The RedTail for Metastatic Solid Tumors, CLD-101 for Recurrent HGG; CLD-201 for Solid Tumors, and CLD-101 (NeuroNova) for Newly Diagnosed High Grade Glioma.
12GF Score

Get the complete analysis for CLDI

Total Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.16
Price